ASCO 2018 | ATLANTIC: durvalumab in the fight against NSCLC
The ATLANTIC trial (NCT02087423) is currently underway to determine the effects of durvalumab on patients with advanced non-small cell lung cancer (NSCLC). Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, outlines the three different arms of the study and differences between them. Dr Garassino also highlights some of the preliminary results, including long-term survival.
Get great new content delivered to your inboxSign up